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Robert Fischer8, Claus Y. Andersen9, Klaus Bühler10,11, Sesh K. Sunkara12, Nikolaos P. Polyzos13, Ida Strina1,
Luigi Carbone1, Fabiola C. Bento2, Daniela Galliano14, Hakan Yarali15, Lan N. Vuong16,17, Michael Grynberg18,
Panagiotis Drakopoulos19,20, Pedro Xavier21, Joaquin Llacer22, Fernando Neuspiller23, Marcos Horton24,
Matheus Roque25, Evangelos Papanikolaou26,27, Manish Banker28, Michael H. Dahan29, Shu Foong30,31,
Herman Tournaye19, Christophe Blockeel19, Alberto Vaiarelli32, Peter Humaidan4,33, Filippo M. Ubaldi32 and on
behalf of the POSEIDON (Patient-Oriented Strategies Encompassing IndividualizeD Oocyte Number) groupAbstract
The prolonged lockdown of health services providing high-complexity fertility treatments –as currently
recommended by many reproductive medicine entities– is detrimental for society as a whole, and infertility patients
in particular. Globally, approximately 0.3% of all infants born every year are conceived using assisted reproductive
technology (ART) treatments. By contrast, the total number of COVID-19 deaths reported so far represents
approximately 1.0% of the total deaths expected to occur worldwide over the first three months of the current
year. It seems, therefore, that the number of infants expected to be conceived and born –but who will not be so
due to the lockdown of infertility services– might be as significant as the total number of deaths attributed to the
COVID-19 pandemic. We herein propose remedies that include a prognostic-stratification of more vulnerable
infertility cases in order to plan a progressive restart of worldwide fertility treatments. At a time when preventing
complications and limiting burdens for national health systems represent relevant issues, our viewpoint might help
competent authorities and health care providers to identify patients who should be prioritized for the continuation
of fertility care in a safe environment.
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Recently, governments around the world announced the
most far-reaching restrictions of personal freedom in
modern history due to COVID-19. The remarkable in-
crease in COVID-19 cases raises the prospect of massive
hospitalizations that no healthcare system in the world
can manage. The urgent need to avoid this scenario is the
justification for the implemented restrictions, and repro-
ductive medicine societies decisively followed by issuing
expert guidance based best judgment. With a solid con-
sensus, the key recommendations for practitioners include
suspension of new fertility treatments –ovulation induc-
tion, intrauterine insemination (IUI), and in vitro
fertilization (IVF)– as well as non-urgent gamete cryo-
preservation, cancellation of all embryo transfers, whether
fresh or frozen and suspension of elective surgery and
non-urgent diagnostic procedures [1, 2]. Exceptions are
those patients who are currently ‘in-cycle’ or who require
urgent fertility preservation due to cancer treatment.
We agree that faced with increasing numbers of coronavirus
infections across the world, no medical society would have
acted differently. However, taking the above mentioned into
account, we would like to raise a novel and constructive view-
point. Our concern is that a prolonged lockdown of fertility
treatment will be detrimental to both patients and society.
Moreover, the fertility community is uncertain about how to
optimally provide care to infertile patients –without com-
promising safety– once the restart of fertility services is estab-
lished. Thus, we aim at proposing remedies to mitigate the
long-term consequences of a prolonged cessation of infertility
treatment and to help regulatory authorities and health care
providers identify which patients might be prioritized for the
continuation of fertility care in a safe environment.
The pandemic facts
At the time of writing (April 23), the global COVID-19
deaths represent approximately 1.0% of total deaths ex-
pected to occur worldwide over the first 3 months of the
current year, with a wide variation in the reported death
rates per country, ranging from 3% in Germany to 13%
in Italy [3]. In total, more than two million COVID-19
cases have been reported, 97% of which have been de-
fined as mild. Among the severe or critical cases, the
overwhelming majority affects people aged 50 and above.
By contrast, the death rate among people at reproductive
age is 0.2%, with an estimated 1.5:1 male to female ratio,
mainly affecting those with pre-existing conditions, in-
cluding cardiovascular disease, diabetes, chronic respira-
tory disease, obesity, hypertension, and cancer [3] .
The interpretation and impact for patients undergoing
assisted reproductive technology treatment
While it is prudent to advocate temporary social distan-
cing and closure of non-emergency health services, wewould like to point at what a prolonged lockdown of fertil-
ity treatment might mean for the society as a whole, and
infertility patients in general. This consideration will focus
on assisted reproductive technology (ART) treatment, par-
ticularly in the low prognosis patients who represent ap-
proximately 30–50% of patients seeking ART [4].
Conservative estimates indicate that over 1.5 million
IVF cycles are carried out every year worldwide, resulting
in approximately 400,000 babies born [5]. In the United
Kingdom and the United States, approximately 3 and 2%,
respectively, of all infants born every year are conceived
using ART [6, 7]. Globally, ART babies represent about
0.3% of the total live birth rate every year [5, 8]. Presently,
we do not know how long the suspension of fertility treat-
ments will last; however, estimates ranging from 3 to 12
months or even longer have been suggested, depending
on how effective governments implement quarantine mea-
sures and how long it takes to acquire herd immunity.
Thus, the number of infants expected to be conceived and
born –but who will be so due to the lockdown of infertility
services– might be as significant as the total number of
deaths attributed to the COVID-19 pandemic.
Along these lines, the ‘time’ variable is crucial for spe-
cific subgroups of infertile women, in particular, patients
with ‘low prognosis’ for success in ART who tends to lose
their fertility potential rapidly. The implications of post-
poning ART treatment under these circumstances de-
mand significant attention. Notably, the probability of
embryo euploidy, i.e., having an exact multiple of the hap-
loid number of chromosomes, declines sharply after the
age of 34 years and is overall lower than 50% for this sub-
group (Supplementary Figure 1) [9]. At ages 35, 36, 37, 38,
39, and 40 years, the relative loss in embryo euploid prob-
ability from the previous year is 6.7, 8.2, 9.8,11.6, 13.6, and
15.7%, respectively (Supplementary Figure 2) [9].
The impact of female age on the success rates of ART
is more dramatic in older than younger patients as more
oocytes are needed –in the former– to obtain at least
one euploid embryo for transfer.
Along these lines, the ART calculator –a clinical pre-
dictive model used to estimate the number of mature
(metaphase II) oocytes needed to obtain at least one eu-
ploid embryo in couples undergoing ART – indicates that
13 (95% confidence interval [CI]: 11–16), 16 (95% CI: 13–
20), and 19 (95% CI: 15–25) oocytes are needed for
women aged 38, 39, and 40 years, respectively [10, 11]. By
contrast, only 5 (95% CI: 4–6) and 6 (95% CI: 5–7) oocytes
are required for patients aged 33 and 34 years to have at
least one euploid embryo [10, 11]. These figures, com-
bined with the proven reduced ovarian reserve in patients
of advanced age, clearly indicate that reproductive out-
comes will be decreased if treatment is further delayed.
The Poseidon group in 2015 introduced new criteria
to identify the ‘low prognosis patient’ undergoing ART
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ous history of ovarian stimulation –if available–, ‘low
prognosis’ patients were stratified into four specific sub-
groups, each of which with a distinct prognosis concern-
ing the likelihood of conceiving and delivering a baby
with the use of ART (Supplementary Figure 3). The pri-
mary aim of the Poseidon criteria was to provide patient
counselling and clinical guidance regarding interventions
that could help these patients conceive in the shortest
possible time. The most vulnerable Poseidon patients are
those within groups 2 and 4, i.e., ageing patients 35 years
or above, with (i) an unexpected suboptimal number of
oocytes retrieved in a previous ART cycle despite a nor-
mal ovarian reserve (group 2), or (ii) low ovarian reserve
in whom the number of oocytes resulting from ovarian
stimulation is invariably low (group 4) [12, 15, 16]. The
reason relates to the impact of maternal age and number
of oocytes on the availability of euploid embryos, and thus,
live birth. In particular, Poseidon group 4 patients are run-
ning out of time, and any further delay in treatment might
imply the loss of a future opportunity to obtain a bio-
logical child. Indeed, the percentage of initiated ART cy-
cles resulting in a live birth is estimated to be 41.5% in
women younger than 35 years; however, these numbers
dramatically decrease with ageing, being less than 5% in
women above 40 years [17].
The impact of COVID-19 for women in need of fertility
preservation
Women affected by cancer or other conditions (e.g..,
autoimmune disorders, systemic lupus erythematosus,
hematologic disorders), who need to undergo gonado-
toxic treatment, require urgent procedures for fertility
preservation [18, 19]. Immediate oocyte or embryo cryo-
preservation could represent the only opportunity to ob-
tain a pregnancy after the end of gonadotoxic treatment.
At present, the prevailing consensus is to allow fertility
preservation programs to continue for oncological pa-
tients. On the other hand, more prudence concerning
embryo transfer is proposed. Notably, as new scenarios
emerge, even embryo transfer could be challenging to
postpone in some specific subgroups of patients. For in-
stance, in women with endocrine responsive breast can-
cers, an international panel of oncologists have proposed a
temporary interruption in endocrine therapy to allow pa-
tients to obtain natural or assisted conception [20, 21]. In
these women, the full course of endocrine therapy, which
for some cases might be at least 5–10 years, could dramat-
ically decrease natural fecundity after finalisation of ther-
apy. According to the POSITIVE trial approach, the
therapeutic suspension ‘window’ should not be longer
than 24months to allow patients to conceive and deliver
[20]. If no conception occurs, patients must restart adju-
vant therapy. If such an approach is validated, andimportantly, the trial is still ongoing, every strategy to ob-
tain a pregnancy within this short timeframe, including
IVF and embryo transfer, should be considered without
further delay.
Besides oncologic disorders, other conditions might
require fertility preservation. A classic example includes
systemic autoimmune diseases (SADs), which are not
uncommon in women of reproductive age. In these pa-
tients, the chronic inflammation might affect the
hypothalamic-pituitary-ovarian axis and the ovaries dir-
ectly, causing impairment of the ovarian reserve [22–24].
Moreover, gonadotoxic drugs (e.g., alkylating agents)
and teratogenic agents (e.g., Mycophenolate mofetil) are
commonly used to control the inflammatory processes
in patients with SADs. In these patients, fertility preser-
vation is conditioned to the “remission window” [25]. In
other words, the inflammatory process has to be re-
strained before ovarian stimulation and pregnancy can
be considered. Thus, it has been recommended that
women with SADs (e.g., systemic lupus erythematosus,
antiphospholipid antibody syndrome, rheumatoid arth-
ritis, systemic sclerosis, Sjögren’s syndrome, mixed con-
nective tissue disease, idiopathic inflammatory
myopathies and vasculitis, among others) only embark
on ART after at least 6 months of clinical remission has
elapsed [25]. Several patients with SADs seeking fertility
might have been planning this ‘window’ for a consider-
able time, which unfortunately occurred during the
COVID-19 crisis –postponing IVF in these patients
compromises their reproductive chances considerably.
Lastly, young patients with a diminished ovarian
reserve and being at risk of premature ovarian insuffi-
ciency (i.e., Poseidon group 3) also represent a “time-
sensitive” category of women [15, 26]. Due to the fact
that Poseidon group 3 patients are younger than 35 years
and, therefore, the oocyte/embryo euploidy rate is over
50%, the number of oocytes required to have at least one
euploid embryo in these patients is lower than in older
patients (e.g., 35 years and older) in whom the oocyte/
embryo euploidy rate is below 50% overall (e.g., Posei-
don groups 2 and 4). Nevertheless, it is not unlikely that
when the ovarian reserve is dramatically reduced, the
remaining window to respond to ovarian stimulation is
narrow. In reality, this scenario is not very different from
the pre-chemotherapy situation. On this basis, we be-
lieve that Poseidon group 3 patients should be allowed
the same permissive approach for fertility preservation
as suggested for women who need to undergo
chemotherapy.
Possible remedies for restarting ART treatments
First of all, the health and psychological consequences of
not only offering the above subgroups of patients ART
but also the impact on the resulting pregnancy need to
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undergoing medical treatment aiming at improving
semen quantity or quality should not be forgotten. Like
men at reproductive age with cancer who are recom-
mended to freeze sperm urgently, these patients should
also be allowed to cryopreserve sperm or to even fertilize
oocytes for subsequent embryo cryopreservation. Thus,
andrological services must be are available for them too.
Secondly, it might take months, or even years, before we
can assess the broader implications of the current re-
strictive measures for patients as well as society. The
damage to the affected patients is difficult to ascertain;
however, removing infertility services for those who need
it most might be even worse than the risks of treating
them at the current time. While the various lockdowns
have slowed the spread of infection, new cases will ap-
pear as soon as measures are loosened.
In this time of uncertainty, we propose some remedies
that we believe give fertility providers and patients alike
greater autonomy, and that could be used to alleviate
the adverse impact of the coronavirus pandemic in the
months to come (Fig. 1).
1. Before any consultation, active COVID-19 infec-
tions and suspected cases should be excluded. Test-
ing patients with the use of molecular or serological
testing should be weighed on an individual basis.
2. ART treatment should be allowed for eligible (i.e.,
with no risk factors that might increase COVID-19
morbidity) ‘low prognosis’ patients (e.g., Poseidon
groups 2, 3, and 4):Fig. 1 COVID − 19 and Assisted Reproductive Technology: proposal for individualii. Poseidon group patients 2 could undergo
ovarian stimulation and IVF for oocyte freezing
or embryo freezing, as appropriate, as the
ovarian reserve is still fair [15];
ii. Poseidon group 3 patients could undergo
ovarian stimulation and ART for oocyte freezing
or embryo freezing as the rate of oocyte and
embryo aneuploidy is relatively low [26];
iii. For Poseidon group 4 patients, multiple
ovarian stimulations (e.g., consecutive
stimulation or DuoStim) and fresh or frozen
embryo transfer –with or without
preimplantation genetic testing (PGT-A)–
should be considered, as appropriate [26].
iv. The ART calculator could be used to estimate
the number of oocytes required to achieve at
least one euploid embryo for transfer [10, 11].
v. Personalizing the gonadotropin dose for ovarian
stimulation and use of a GnRH antagonist
protocol, followed by GnRH agonist triggering,
and elective freezing of oocytes or embryos
should be the first choice during this emergency
period.
vi. Poseidon groups 2 and 4 patients with
comorbidities (e.g., smokers) should be advised
to change the lifestyle immediately, as these
changes could have a positive impact on overall
health and ART success.3. Fertility preservation should be allowed in
women affected by SADs if under clinical
remission.zed clinical management
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should be available during any treatment aiming at
improving sperm quantity/quality. Thus, we
propose that these services are not restricted to
oncological patients only.
5. Telehealth and phone counselling for infertile
patients should be encouraged.
6. Face to face visits should be limited for infertile
patients who demand immediate treatment. Proper
personal protective equipment (PPE) should be
used by patients and healthcare providers during
care provision.
7. ART treatment should be carried out, as much as
possible, in free-standing medical facilities, avoiding
the diversion of clinical resources, or reduction of
hospital capacity that could otherwise be used to
care for COVID-19 patients.
8. In closed-controlled air systems, the airflow might
produce an increase in the viral spread from poten-
tial asymptomatic patients. Thus, special attention
should be given to air quality control, including the
use of air filtration systems and air pressurization,
particularly in surgical and laboratory areas [27].
9. Adherence to regulatory infection prevention
recommendations should be of utmost importance
for patients and health practitioners [28]. This
advice includes the use of appropriate PPE by staff,
adherence to social distancing measures for staff
and patients, and staggering appointments so that
no patients are waiting together in the clinic
waiting area.
10. The importance of training of ART staff (clinicians,
embryologists, nurses) on PPE needs and usage is
stressed.
11. Good standard laboratory practices should be
strictly applied when handling gametes and
embryos within the embryology and andrology
laboratories.
12. A thorough discussion between patients and health
care professionals should be made for responsible
shared decisions, and psychological support should
be an option for those in need.
13. Advanced planning should guide the restart of ART
services. Working groups and quality managers
should design scenarios on which patients to
prioritize, how working lists should be filled and
staff scheduling.
Practical considerations for ART treatment providers
During the coming weeks, we should continue to look
critically and dispassionately at the COVID-19 pan-
demic. Our recommendations are unlikely to create any
further burden to the medical infrastructure as ART in
the population mentioned above is virtually free ofcomplications. We realize that much is unknown about
the implications of COVID-19 for early- and late preg-
nancy, including maternal-fetal transmission and terato-
genicity [29, 30]. However, pregnancy can act as a
comorbidity, and we, therefore, currently recommend
against conception by ART in most cases. However, it
should also be acknowledged that new serology testing is
being developed to help identify individuals who have
had the infection and have recovered, suggesting that
those people are now immune to the virus and could be
allowed IVF treatment [31]. Likewise, as IVF health care
professionals recover from COVID-19 infections and ac-
quire immunity, there will be less risk of recommencing
care, particularly in COVID-19 recovered patients.
Along these lines, immune patients will have a low risk
of pregnancy complications in the event of an embryo
transfer, or of propagating the disease when attending a
medical facility. Yet, the accuracy of these tests has been
debated and it is still unclear how long any immunity
lasts and if reinfection is possible [32].
Given the likelihood that this pandemic will continue
for many months ahead, we must keep an open mind,
and look for what is - and not for fear of what might be.Future perspectives
What we visualize as a future scenario is a gradual re-
start of “less urgent” infertility treatments, which will fol-
low different phases. The dilemma of how ART services
are restarted after the present lockdown is genuine, as
every country will follow a different recovery curve. Im-
portantly, it should be considered that contamination of
patients and medical staff could occur with COVID-19
when ART care is restarted, particularly in the context
of asymptomatic shedding. Thus, we reiterate the rec-
ommendations given above that care should only be
restarted if social distancing can be maintained, proper
PPE be available and used, areas regularly disinfected,
and screening for signs and symptoms of the infection
undertaken before allowing patients embark on ART
treatments.Conclusions
This article provides a viewpoint to help both compe-
tent authorities and health care providers to better
identify priorities and remedies for infertile patients
impacted by the COVID-19 pandemic restrictions. In
a moment when preventing complications and limit-
ing burdens for national health systems could still
represent a relevant issue, the correct prognostic
stratification of patients and the identification of more
“time-sensitive” cases is crucial for guiding the grad-
ual restart of ART services.
Alviggi et al. Reproductive Biology and Endocrinology           (2020) 18:45 Page 6 of 7Supplementary information
Supplementary information accompanies this paper at https://doi.org/10.
1186/s12958-020-00605-z.
Additional file 1 Supplementary Figure 1. Logistic regression analysis
of 1220 trophectoderm biopsies from 436 patients undergoing
intracytoplasmic sperm injection and preimplantation genetic testing for
aneuploidy by next-generation sequence testing. The plot depicts the fit-
ted probabilities (with 95% confidence intervals) of blastocyst euploidy as
a function of female age. Reprinted with permission of Edizioni Minerva
Medica from Esteves et al. (9).
Additional file 2 Supplementary Figure 2. The graph shows the
percent decrease in the probability of a embryo at the blastocyst stage
being euploid, which increases progressively with every year of female
age. The percentages shown represent the relative loss from the previous
year. Reprinted with permission of Edizioni Minerva Medica from Esteves
et al. (9).
Additional file 3 Supplementary Figure 3. POSEIDON criteria of low
prognosis patients in ART. The novel system relies on female age, ovarian
reserve markers, ovarian sensitivity to exogenous gonadotropin, and the
number of oocytes retrieved, which will both identify the patients with
low prognosis and stratify such patients into one of four groups of
women with “expected” or “unexpected” impaired ovarian response to
exogenous gonadotropin stimulation. According to these criteria, four
distinct groups of low prognosis patients can be established (left). Group
1: Patients < 35 years with sufficient prestimulation ovarian reserve
parameters (AFC ≥5, AMH ≥1.2 ng/mL) and with an unexpected poor or
suboptimal ovarian response. This group is further divided into subgroup
1a, constituted by patients with fewer than four oocytes, and subgroup
1b, constituted by patients with four to nine oocytes retrieved after
standard ovarian stimulation. Group 2: Patients ≥35 years with sufficient
prestimulation. Ovarian reserve parameters (AFC ≥5, AMH ≥1.2 ng/mL)
and with an unexpected poor or suboptimal ovarian response. This
group is further divided into subgroup 2a, constituted by patients with
fewer than four oocytes, and subgroup 2b, constituted by patients with
four to nine oocytes retrieved after standard ovarian stimulation. Group 3:
Patients < 35 years with poor ovarian reserve prestimulation parameters
(AFC < 5, AMH < 1.2 ng/mL). Group 4: Patients ≥35 years with poor
ovarian reserve prestimulation parameters (AFC < 5, AMH. < 1.2 ng/mL).
Owing to low oocyte numbers and less embryos produced, POSEIDON
patients have lower cumulative live birth rates per started cycle than
non-POSEIDON counterparts. However, the prognosis is differentially af-
fected by oocyte quantity and female age, as the latter relates to the risk
of embryo aneuploidy (right). Art drawing by Chloé Xilinas. Reprint from
Esteves et al. (4). This is an open-access article distributed under the
terms of the Creative Commons Attribution License (CC BY).Abbreviations
ART: Assisted reproductive technology; CI: Confidence interval; COVID-
19: Coronavirus disease 2019; IUI: Intrauterine insemination; IVF: In vitro
fertilization; POSEIDON: Patient-oriented strategies encompassing
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